MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Absci Corporation (NASDAQ: ABSI)*
Organization & Developments: AbSci
Parents
Absci Corporation (NASDAQ: ABSI)*
Children
*AbSci is a synthetic biology company that translates ideas into drugs with a platform technology that reinvents the biopharmaceutical drug discovery process.
*AbSci’s synthetic biology platform technology offers fully-integrated, AI-assisted, de novo drug discovery and cell line development
*AI-driven protein design to enhance mRNA vaccine efficacy.
*Denovium AI platform
*Protein Printing™ Platform Technology
*They custom engineer E. coli to create novel complex biologics in their full length format while simultaneously developing production cell lines
2022: Vancouver biotech firm Absci lays off workers amid economic uncertainty
2023: Biotech company Absci lays off 30 employees, about 15% of staff
2023: Vancouver biotech firm Absci inks 10 deals for drug discovery programs worth $1 billion_columbian
2024: Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
2024: Absci and Twist Bioscience Team Up to Redefine Antibody Discovery with AI
2024: Absci Corporation: Struggling To Live Up To Its AI Promise
2024: Absci: Differentiated Antibody Discovery Play
2024: Absci: Embryonic Pipeline Looks Expensive Relative To Peers
2025: Absci Looks Cheap And Positioned For Growth With AMD's AI Backing_seekingalpha.com
2025: Absci signals expanded clinical pipeline with ABS-101 in Phase I and ABS-201 targeting early 2026 trial
2025: Absci: Still A Work In Progress, Fighting To Survive
Jumps
*Key People: AbSci
Finance & Acquisitions: AbSci